MediGene to Present at Rodman & Renshaw Techvest 6th Annual Healthcare Conference MARTINSRIED, Germany and SAN DIEGO, Oct. 22 /PRNewswire-FirstCall/ -- The German-American biotech company MediGene AG (Frankfurt, Prime Standard: MDG) announced today that the company will be presenting at the Rodman & Renshaw Techvest 6th Annual Healthcare Conference on Wednesday, October 27, 2004 at the Waldorf Astoria Hotel, 301 Park Avenue, New York, NY. Alexander Dexne, Chief Financial Officer, will provide an overview of the company and an update on clinical and business activities. Mr. Dexne will present at 4:35 PM (ET) in the Starlight Roof Center. MediGene has a mature cancer drug pipeline with one drug on the European market (Eligard(R) against prostate cancer) and several drug candidates undergoing clinical phase I - III trials such as Polyphenon(R) E against skin tumors which will have completed phase III trial by the end of 2004. In addition, MediGene possesses innovative platform technologies with its HSV technology and the newly acquired EndoTAG technology. The EndoTAG drug candidates aim at a novel method of cancer therapy by "starving out" tumors. They utilize the already approved and applied therapy of anti-angiogenesis (suppressing tumor vascularization), while adding a further and unique activity: the cutting-edge carrier system of lipid complexes facilitates a novel application method of established cytostatic drugs (e.g. Taxane), intended to cause specific attachment and destruction of tumor blood vessels ("neovascular targeting"). MediGene will continue clinical development of the drug candidate EndoTAG-1 which has already undergone several clinical phase 1 trials in different cancer indications. This press release contains forward-looking statements that involve risks and uncertainties. The forward-looking statements contained herein represent the judgement of MediGene as of the date of this release. These forward- looking statements are no guarantees for future performance, and the forward- looking events discussed in this press release may not occur. MediGene disclaims any intent or obligation to update any of these forward-looking statements. MediGene(TM) is a trademark of MediGene A. DATASOURCE: MediGene AG CONTACT: Thomas Fechtner, +1-212-477-9007, for MediGene AG

Copyright